<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01141270</url>
  </required_header>
  <id_info>
    <org_study_id>FIN1001</org_study_id>
    <nct_id>NCT01141270</nct_id>
  </id_info>
  <brief_title>Comparative Pharmacokinetics of AFOLIA and Gonal-f速 After Single Subcutaneous Application</brief_title>
  <official_title>Comparative Pharmacokinetics of AFOLIA and Gonal-f速 After Single Subcutaneous Application. A Randomised, Open Label, Cross Over Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Polymun Scientific GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Polymun Scientific GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparative pharmacokinetics study after single subcutaneous application of AFOLIA and the&#xD;
      reference product (Gonal-f速).&#xD;
&#xD;
      Objective: To demonstrate equivalence within the 80%-125% margin of the reference product for&#xD;
      the area under the curve (AUC) of AFOLIA compared to (Gonal-f速).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the serum concentration curve (AUC) of FSH</measure>
    <time_frame>0 -192h after FSH injection</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>AFOLIA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>225 IU sc</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gonal-f</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>225 IU sc</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AFOLIA</intervention_name>
    <description>single sc injection, 225 IU</description>
    <arm_group_label>AFOLIA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gonal-f</intervention_name>
    <description>single sc injection, 225IU</description>
    <arm_group_label>Gonal-f</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy female volunteers&#xD;
&#xD;
          -  Age between 18-38 years&#xD;
&#xD;
          -  Body mass index 17-29 kg/m2&#xD;
&#xD;
          -  Woman of child bearing potential must agree to practice effective barrier methods for&#xD;
             birth control&#xD;
&#xD;
          -  Use of oral contraceptives for at least 3 months before study entry&#xD;
&#xD;
          -  Regular menstruation cycle (25-34 days) before initiation of oral contraception&#xD;
&#xD;
          -  Presence of both ovaries&#xD;
&#xD;
          -  Normal findings in medical history and physical and gynaecological examination unless&#xD;
             the investigator considers an abnormality to be clinically irrelevant for this study&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Polycystic ovary syndrome (PCOS)&#xD;
&#xD;
          -  History of hypersensitivity to FSH (Ovary Hyperstimulation Syndrome, OHSS)&#xD;
&#xD;
          -  Impaired thyroid function (treated or untreated)&#xD;
&#xD;
          -  History of malignant disease&#xD;
&#xD;
          -  AST and/or ALAT &gt; 2 x ULN&#xD;
&#xD;
          -  Other clinically relevant findings (ECG, blood pressure, physical, gynecological&#xD;
             examination, laboratory examination)&#xD;
&#xD;
          -  Smoking habits of more than 5 cigarettes per day&#xD;
&#xD;
          -  Abuse of alcoholic beverages and drugs&#xD;
&#xD;
          -  Participation in a clinical trial within 3 weeks prior to the study&#xD;
&#xD;
          -  Foreseen inability to attend to scheduled study visits&#xD;
&#xD;
          -  Symptoms of a clinically relevant illness during 3 weeks prior the first study day&#xD;
&#xD;
          -  Pregnancy or lactation period&#xD;
&#xD;
          -  Any medical condition that, in the opinion of the investigator, would interfere with&#xD;
             safety of the subject or interference of the objectives of the study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Wolzt, aoUniv.Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University Vienna</affiliation>
  </overall_official>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>June 9, 2010</study_first_submitted>
  <study_first_submitted_qc>June 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2010</study_first_posted>
  <last_update_submitted>August 3, 2010</last_update_submitted>
  <last_update_submitted_qc>August 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2010</last_update_posted>
  <responsible_party>
    <name_title>Brigitta Vcelar PhD</name_title>
    <organization>Polymun Scientific GmbH</organization>
  </responsible_party>
  <keyword>recombinant human follicle stimulating hormone</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>bioequivalence</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

